ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiovascular Metabolism
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1593688
This article is part of the Research TopicAdvancing Cardiovascular Disease Understanding Through Metabolomics and Metabolic Regulation NetworksView all 7 articles
Exploring the molecular intersection for hypertension, hyperlipidemia and their comorbid conditions through multi-omics approaches
Provisionally accepted
- Yan'an Hospital Affiliated To Kunming Medical University, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Hypertension and hyperlipidemia are interconnected conditions that heighten cardiovascular risk, yet their intricate multi-scale molecular signatures remain inadequately mapped. This study aimed to conduct an integrated multi-omics investigation to unravel the key pathways and biomarkers underlying hypertension, hyperlipidemia, and both conditions. Methods: Metabolomic analysis was performed on serum samples and metagenomic analysis on fecal samples collected from individuals with hypertension (n = 16), hyperlipidemia (n = 19), or both conditions concurrently (n = 20). In addition, 20 healthy individuals were recruited as controls. Results: Metabolomics uncovered altered levels of sphingolipids, phosphatidylcholines, glycylprolines, and nucleic acid metabolites, which may be associated with changes in vascular tone, lipid and protein homeostasis, and thyroid signaling. Metagenomics showed depletion in the abundance of the Fibrobacteres phylum. Altered abundances of Escherichia coli and Bacteroides vulgatus were also observed, which were correlated with deviations in lipid and carbohydrate metabolism. Sphingomyelin d18:1/16:0 and sphingomyelin d18:1/24:1(15Z) were the key metabolites that were identified as potential diagnostic biomarkers across conditions. Microbial taxa such as Enterococcus cecorum, Lachnospiraceae bacterium, Prevotella histicola, and Flavobacterium discriminated these diseases. Pathway analysis revealed glycoxylate, amino acid, purine, and sphingolipid metabolism alterations intersecting hypertension and hyperlipidemia. Conclusions: This multi-omics landscape of comorbid disease pathways and biomarkers lays the foundation for precision diagnosis and treatment of prevalent cardiovascular conditions.
Keywords: multi-omics, Metabolomics, Metagenomics, comorbidities, Sphingolipids, microbiome, biomarkers
Received: 14 Mar 2025; Accepted: 23 Sep 2025.
Copyright: © 2025 Li, Zhou, Ji, Tian, Meng, Li, Guo, He, Dao and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xingfang Jin, jinxf177@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.